Advanz Pharma Germany GmbH secures contract for Pharmaceutical products conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient lanreotide ATC H01CB03 for the period 01072025 - 30062026 plus extension option 1x 12 months

Germany, June 1 -- Germany based Advanz Pharma Germany GmbH has secured contract from DAK-Gesundheit for Pharmaceutical products conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient lanreotide ATC H01CB03 for the period 01072025 - 30062026 plus extension option 1x 12 months . The value of the contract is not disclosed .

Published by HT Digital Content Services with permission from Pivotal Sources....